Engineering strain and application thereof in fermentation production of L-aminocyclopropane-2-carboxylic acid
By constructing the engineering strain in E. coli BW25113, the biosynthesis pathway of L-AZE was optimized, and the problem of low L-AZE yield was solved, efficient production was achieved, industrial demands were met and by-product accumulation was reduced.
Patent Information
- Application Number
- CN202411258762.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to produce L-aminocyclopropane-2-carboxylic acid (L-AZE) with anti-powder mildew activity on a large scale, and its synthetic efficiency in Pseudomonas aeruginosa is low and cannot meet industrial needs.
By translocating the plasmid pYB1s-azeJ and metK genes into E. coli BW25113, the engineered strain was constructed, and the popular cycle was introduced, the PRPP supply and ATP-adenine cycle were enhanced, and the biosynthetic pathway of L-AZE was optimized to improve yield.
The production of L-AZE has been significantly improved to 437.3 mg/L, meeting the demand for large-scale production, reducing the accumulation of by-product MTA, and enhancing biosynthesis efficiency.
Smart Images

Figure CN119060927A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioengineering. Background Art
[0002] Cucurbit powdery mildew is a devastating leaf disease caused by Podosphaera xanthii. Traditionally, it has relied on chemical pesticides for control, but these pesticides have long-term adverse effects on the environment. Therefore, it is necessary to develop an environmentally friendly control method.
[0003] L-Aminocyclopropane-2-carboxylic acid (L-AZE) is a naturally occurring non-protein amino acid that has been shown to have antibacterial and antifungal activity, particularly against powdery mildew. L-AZE is structurally identical to L-proline, except that its ring has one less carbon than L-proline. L-AZE was first discovered by Fowden in lilies, poinciana, and sugar beets. It acts as an intermediate in plant allelopathic effects by hindering the growth of competing vegetation and poisoning predators, an effect that results from L-AZE being misincorporated into proteins to replace proline. Substitution of L-proline by L-AZE results in a change in the tertiary structure of the protein, and because L-AZE rotates at a helix angle of approximately 15° less than L-proline, it should act as a potent phytotoxin in some plant species. L-AZE is also a key component of deoxyxyzinic acid and nicotinamide, both of which are potent phytostimulants that help plants absorb iron from the soil. Coincidentally, L-AZE was also found in the Gram-negative bacterium Pseudomonas aeruginosa. It is a monomer of a unique small molecule non-ribosomal polypeptide secondary metabolite with antibacterial, antitumor, and immunosuppressive biological activities. L-AZE has also been used for the modification of polypeptide structures and the preparation of various inhibitors, such as harmful algal growth inhibitors and liver fibrosis inhibitors. Notably, recent studies have shown that L-AZE has extremely strong antifungal activity against Podosphaera xanthii and has a significant therapeutic effect on powdery mildew. As a non-protein amino acid naturally present in plants, L-AZE is considered to be a degradable powdery mildew control agent with low toxicity.
[0004] The first validated L-AZE synthetase, encoded by the azeJ (PA3335) gene, has been discovered in Pseudomonas aeruginosa PAO1. This enzyme generates L-AZE directly from S-adenosylmethionine (AdoMet) and produces 5'-methylthioadenosine (MTA) as a byproduct. AdoMet is synthesized from methionine and ATP by S-adenosylmethionine synthetase (encoded by the metK gene). The byproduct MTA is a nucleoside that can regenerate methionine via a methionine regeneration pathway (known as the Poplar cycle) to form adenine and formate. Although the L-AZE synthesis pathway in P. aeruginosa has been identified, the fact that this is an opportunistic pathogen has hampered its use as a host for industrial production of L-AZE. In addition, the low synthesis efficiency in plants does not meet the needs of large-scale production. Summary of the invention
[0005] In view of this, the present invention provides an engineered strain, which is obtained by transferring plasmid pYB1s-azeJ into Escherichia coli BW25113; the plasmid pYB1s-azeJ is obtained by transferring azeJ gene into pYB1s plasmid and driving it with PBAD promoter.
[0006] Furthermore, the metK gene was transferred into the plasmid pYB1s-azeJ to obtain the plasmid pYB1s-azeJ-metK, and then the plasmid pYB1s-azeJ-metK was transferred into Escherichia coli BW25113 to obtain.
[0007] Furthermore, it also includes introducing plasmid pMTN into the strain; the plasmid pMTN expresses mtnK gene, mtnA gene, mtnB gene, mtnC gene and mtnD gene on the pFS91G backbone through L-arabinose inducible promoter PBAD.
[0008] Furthermore, in the engineered strain, the purR gene was knocked out.
[0009] Furthermore, in the engineered strain, the prs gene was transferred into the trpR site.
[0010] Furthermore, in the engineered strain, an apt gene was integrated at the yeeP site.
[0011] Furthermore, in the engineered strain, the adk gene was transferred into the amn locus to obtain it.
[0012] The invention also provides application of the engineered strain in producing L-AZE by fermentation.
[0013] The engineered strain provided by the invention can greatly increase the yield of L-AZE. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is a schematic diagram of the biosynthetic pathway of L-AZE.
[0015] Figure 2 The chassis strain was constructed in E. coli BW25113 to accumulate L-AZE map.
[0016] Figure 3 is to construct a “Yang cycle” to promote MTA recovery and increase L-AZE yield.
[0017] Figure 4 The yield map of L-AZE is to increase by enhancing the PRPP supply.
[0018] Figure 5 : Further improving the production of L-AZE by strengthening the ATP-adenine cycle. DETAILED DESCRIPTION
[0019] Example
[0020] 1. Design of L-AZE biosynthetic pathway
[0021] L-AZE is generated by L-AZE synthetase catalyzing the direct precursor AdoMet, accompanied by the byproduct MTA. L-methionine can be activated by S-adenosylmethionine synthetase and ATP to form the direct precursor AdoMet. MTA is a metabolite in cell cycle regulation and a potent apoptosis inducer. The accumulation of MTA is not conducive to the biosynthesis of L-AZE. Therefore, the treatment of the byproduct MTA is the key to improving the efficiency of L-AZE biosynthesis. The treatment of MTA is mediated by the L-methionine regeneration pathway (also known as the Yang cycle). First, MTA is hydrolyzed by methylthioadenosine ribose hydrolase (Mtn) to form adenine and 5-methylthio-D-ribose. 5-Methylthio-D-ribose can be converted into S-methylthio-5-thio-D-ribose-1-phosphate under the action of 5-methylthioribokinase (MtnK) catalyzing the hydrolysis of ATP. The cyclization reaction of S-methylthio-5-thio-D-ribose-1-phosphate is catalyzed by methylthioribose-1-phosphate isomerase (MtnA). Subsequently, the cyclized S-methylthio-5-thio-D-ribose-1-phosphate is converted into 2-oxo-4-methylthiobutyrate by the combined action of hydrolase (MtnB), phosphohydrolase (MtnC) and dioxygenase (MtnD), with formate generated as a byproduct. 2-Oxo-4-methylthiobutyrate is ultimately converted into methionine by a complex aminotransferase system. Therefore, the introduction of the Poplar cycle is expected to enhance the production of L-AZE by alleviating the accumulation of MTA.
[0022] In summary, 1 mol of MTA is recycled into 1 mol of L-methionine, 1 mol of adenine, and 1 mol of formate (Equation 1), where L-methionine will participate in another round of L-AZE biosynthesis ( Figure 1 ). Formate can be converted to CO2 by formate dehydrogenase (Fdh). The net production of 1 mole of adenine can be regenerated into ATP through the purine regeneration pathway with the input of one mole of PRPP (5-phosphoribosyl-1-pyrophosphate) (Equation 2).
[0023] In general, all carbon inputs in our design come from PRPP, which can be summarized in Equation 3.
[0024] Overall metabolic pathway design Figure 1 shown.
[0025] MTA+ O2 + NH4 + ==Adenine + Formate + L-Methionine + H + (1)
[0026] Adenine + ATP + PRPP == 2ATP (2)
[0027] PRPP + NH4 + + O2 == L-AZE+ CO2 + H + (3)
[0028] 2. Construction of chassis strains in E. coli to accumulate L-AZE
[0029] The azeJ (PA3335) gene encoding L-AZE synthetase (Gene Bank ID: 882500) was constructed into the pYB1s plasmid using seamless cloning to generate the plasmid pYB1s-azeJ. The generated plasmid sequence is shown in SEQ ID No.1.
[0030] Since AdoMet is the direct precursor of L-AZE, enhancing its yield is considered an effective strategy to improve L-AZE production.
[0031] Therefore, the metK gene encoding AdoMet synthetase (Gene Bank ID: AIN33302.1) was further introduced into the pYB1s-azeJ plasmid to generate the plasmid pYB1s-azeJ-metK. The generated plasmid sequence is shown in SEQ ID No.2.
[0032] Plasmids pYB1s, pYB1s-azeJ and pYB1s-azeJ-metK were introduced into Escherichia coli BW25113 to obtain strains AZE00, AZE01 and AZE02, respectively.
[0033] A single colony of recombinant E. coli was inoculated into LB medium and grown overnight at 37°C (200 rpm) in the presence of the required antibiotics (gentamicin 50 μg / mL, kanamycin 50 μg / mL). 600 =0.6-0.8), 2.0 g / L arabinose was added to the culture medium, and the temperature was adjusted to 24°C to induce gene expression. The strain was collected, washed, and resuspended in 50 mM phosphate buffer (pH 7.4) to a final cell density of OD 600 =10. Add 20g / L glucose as substrate to the suspension for reaction. Under the guidance of phenol red indicator, add 10% ammonia water, and maintain the pH value at 6.8-7.4. The reaction is carried out on a shaker with a temperature of 37°C and a speed of 200rpm. Take samples regularly to measure the product generation.
[0034] The content of L-Aze was analyzed by high performance liquid chromatography (HPLC, Agilent 1260) and reverse phase chromatography column 120EC-C18 column (4.6×150mm, 2.7μm, Agilent). The HPLC conditions were: column temperature 40°C, mobile phase A was 0.1% (v / v) formic acid aqueous solution, mobile phase B was acetonitrile, mobile phase A:B=65:35, flow rate 1.0mL / min. Derivatization with dinitrofluorobenzene (DNFB) at 60°C for 1h was performed and then detected, and filtered with a 0.22μm polyethersulfone (PES) membrane (Tianjin, Jinteng). The absorbance was measured at 360nm using a diode array detector (DAD) to determine the analyte concentration. All experiments were performed independently in triplicate, and the data were expressed as mean ± standard deviation (SD).
[0035] like Figure 2 As shown in a, a new peak was detected by HPLC at 8.2 minutes in the liquid supernatant of AZE01 compared with AZE00. The standard substance showed the same retention time at 8.2 minutes, indicating that the initial production of L-AZE had been successfully achieved. AZE01 accumulated 56.4 mg / L L-Aze. In addition, AZE02 accumulated 61.9 mg / L L-AZE, which was 9.7% higher than that of AZE01, indicating that the overexpression of the metK gene had a positive effect on L-AZE production. Figure 2 As shown in b.
[0036] 3. Build a “Yang cycle” to promote MTA recovery and increase L-AZE production
[0037] MTA recovery is a key challenge in L-AZE production because its accumulation can lead to product inhibition of L-AZE synthetase and global adverse effects on host cells.
[0038] First, adenine in MTA is cleaved by the Mtn enzyme to release 5-methylthio-D-ribose. However, due to the lack of degradation ability of E. coli, these substances will be excreted from the cells and inevitably accumulate in the culture medium. MTA concentrations exceeding 1 mM will inhibit the growth of E. coli. Therefore, it is necessary to construct an effective degradation pathway in E. coli to recycle MTA to promote better L-AZE production.
[0039] The present invention introduces a complete Yang cycle into Escherichia coli BW25113. Figure 3 a)
[0040] The 5-methylthioribokinase (mtnK) gene (Gene Bank ID: AGA22118.1) was amplified from Bacillus subtilis 168, and the methylthioribose-1-phosphate isomerase (mtnA) gene (Gene Bank ID: 882801), methylthioribitol-1-phosphate dehydratase (mtnB) gene (Gene Bank ID: 877627), enolase-phosphatase (mtnC) gene (Gene Bank ID: 878111) and 1,2-dihydroxy-3-keto-5-methylthiopentyl dioxygenase (mtnD) gene (Gene Bank ID: 877764) were amplified from Pseudomonas aeruginosa PAO1. Subsequently, we expressed these genes on the pFS91G (sc101 ori, GmR) backbone through the L-arabinose-inducible promoter PBAD to obtain the plasmid pMTN ( Figure 3 b). The pMTN plasmid sequence is shown in SEQ ID No. 3.
[0041] Then plasmid pMTN and empty vector pFS91G were introduced into Escherichia coli BW25113 to obtain Yang-circulating strains.
[0042] The ability to recycle sulfur from MTA to promote growth was tested in sulfur-limited M9 medium. The strains were harvested, washed three times, and resuspended to a final cell density of OD600 = 0.5 in sulfur-free M9 medium without a carbon source. The cells were then starved for 2 hours to deplete endogenous nutrients. After starvation, 4 g / L glucose was added to the medium as a carbon source. When needed, 1 mm MTA was added to the medium as a sulfur source. Samples were taken regularly to measure cell growth.
[0043] When 1 mM MTA was added to provide a sulfur source for cell growth, the strain containing the poplar cycle showed a significant growth advantage.
[0044] Subsequently, the plasmid pMTN carrying the poplar cycle gene was introduced into the AZE02 strain to obtain the strain AZE03. The L-AZE production of the AZE03 strain increased significantly by 4.7 times to 334.7 mg / L ( Figure 3 c).
[0045] 4. Increase L-AZE production by increasing PRPP supply
[0046] This patent uses CRISPR / Cas9 technology to achieve gene knockout, insertion and replacement in the Escherichia coli genome.
[0047] The specific operation method is recorded in detail in the literature
[0048] “Multigene Editing in the Escherichia coli Genome via the CRISPR-Cas9System; Applied Environmental”
[0049] Microbiology.2015,81(7):2506-2514".
[0050] First, the purR gene (GeneBank ID: 945226) was deleted from the AZE03 strain to obtain the AZE04 strain, and an additional copy of the prs gene (Gene Bank ID: 945772) controlled by the prs promoter itself was integrated into the trpR (Gene Bank ID: 948917) site to generate the AZE05 strain. Figure 4 As shown, the L-AZE production concentration in the AZE04 strain increased to 357.2 mg / L, which was 6.7% higher than that of AZE03, while the L-AZE titer of the AZE05 strain increased to 398.9 mg / L, which was 11.7% higher than that of AZE04.
[0051] 5. Further increase the production of L-AZE by strengthening the ATP-adenine cycle
[0052] While restoring MTA in the Yang cycle, an equimolar amount of adenine is produced. Adenine can further regenerate ATP through the ATP-adenine cycle. Therefore, strengthening the ATP-adenine cycle will contribute to the production of L-AZE, as ATP is also a key factor involved in the process. Adenine and PRPP are converted into AMP and diphosphate by the action of adenine phosphoribosyltransferase (EC 2.7.1.20), which is encoded by the apt gene (Gene Bank ID: 945113). We integrated a copy of the apt gene driven by its own promoter Papt at the yeeP (Gene Bank ID: 946524) site of AZE05 to generate the AZE06 strain. The L-AZE titer of AZE06 increased by 4.7% (as shown in Figure 2). Figure 5 As shown), it reached 417.7 mg / L.
[0053] In addition, AMP nucleosidase (EC 3.2.2.4), encoded by the amn gene (Gene Bank ID: 946508), catalyzes the hydrolysis of the N-glycosidic bond of AMP in E. coli to generate ribose 5-phosphate and adenine. It has been reported that deletion of the amn gene has been shown to promote the accumulation of ATP in E. coli. ATP-AMP phosphotransferase (EC 2.7.4.3), encoded by the adk gene, catalyzes the transfer of phosphate groups between ATP and AMP to generate 2 moles of ADP. Subsequently, we integrated a copy of the adk gene (Gene Bank ID: 945097) into the amn site of the AZE06 strain to generate the AZE07 strain. Compared with the AZE06 strain, the L-AZE production of the AZE07 strain was further increased by 3.9%, and the titer reached 437.3 mg / L ( Figure 5 ).
Claims
1. An engineered strain, characterized in that: Plasmid pYB1s-azeJ was transformed into Escherichia coli BW25113; The sequence of the plasmid pYB1s-azeJ is shown as SEQ ID No.
1.
2. The engineered strain according to claim 1, characterized in that The metK gene is transferred into the plasmid pYB1s-azeJ to obtain the plasmid pYB1s-azeJ-metK, and then the plasmid pYB1s-azeJ-metK is transferred into Escherichia coli BW25113 to obtain; The sequence of the plasmid pYB1s-azeJ-metK is shown in SEQ ID No.
2.
3. The engineered strain according to claim 2, characterized in that It also includes introducing plasmid pMTN into the strain described in claim 2; The sequence of the plasmid pMTN is shown in SEQ ID No.
3.
4. The engineered strain according to claim 3, characterized in that Obtained by knocking out the purR gene.
5. The engineered strain according to claim 4, characterized in that It is obtained by transferring the prs gene into the trpR site.
6. The engineered strain according to claim 5, characterized in that Obtained after integration of an apt gene at the yeeP site.
7. The engineered strain according to claim 5, characterized in that Obtained by transferring the adk gene into the amn locus.
8. Use of the engineered strain according to any one of claims 1 to 7 in fermentation to produce L-AZE.
9. Use of the engineered strain according to any one of claims 4 or 5 in fermentation to produce L-AZE, characterized in that: Enhance PRPP supply.
10. Use of the engineered strain according to any one of claims 6 or 7 in fermentation to produce L-AZE, characterized in that: The reaction of strengthening the ATP-adenine cycle is as follows: Adenine+ATP+PRPP==2ATP.
